Cargando…
Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma
SIMPLE SUMMARY: During the last decades, the CA 19-9 blood test has been the only widely used biomarker in patients with pancreatic ductal adenocarcinoma (PDAC). Given the poor prognosis and staggering mortality rates of this type of cancer, partly due to late diagnosis, new and easily available bio...
Autores principales: | Stuhr, Liva K., Madsen, Kasper, Johansen, Astrid Z., Chen, Inna M., Hansen, Carsten P., Jensen, Lars H., Hansen, Torben F., Kløve-Mogensen, Kirstine, Nielsen, Kaspar R., Johansen, Julia S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913074/ https://www.ncbi.nlm.nih.gov/pubmed/36765852 http://dx.doi.org/10.3390/cancers15030897 |
Ejemplares similares
-
Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma
por: Nissen, Neel I., et al.
Publicado: (2022) -
High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients with pancreatic ductal adenocarcinoma
por: Nissen, Neel I., et al.
Publicado: (2023) -
Relationship Between sCD163 and mCD163 and Their Implication in the Detection and Typing of Leprosy
por: Farag, Azza Gaber Antar, et al.
Publicado: (2020) -
Macrophage Biomarkers sCD163 and sSIRPα in Serum Predict Mortality in Sarcoma Patients
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2023) -
Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy
por: Lindgaard, Sidsel C., et al.
Publicado: (2022)